Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
Abstract Background There is no established treatment after failure of proven therapies for patients with metastatic renal cell carcinoma. Case presentation A 66-year-old Japanese man with metastatic renal cell carcinoma became refractory to interferon α and sunitinib therapies. He started treatment...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-04-01
|
| Series: | Journal of Medical Case Reports |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13256-019-2041-8 |
| _version_ | 1818383556725964800 |
|---|---|
| author | Masaki Murata Yohei Ikeda Go Hasegawa Yuki Nakagawa Tsutomu Nishiyama |
| author_facet | Masaki Murata Yohei Ikeda Go Hasegawa Yuki Nakagawa Tsutomu Nishiyama |
| author_sort | Masaki Murata |
| collection | DOAJ |
| description | Abstract Background There is no established treatment after failure of proven therapies for patients with metastatic renal cell carcinoma. Case presentation A 66-year-old Japanese man with metastatic renal cell carcinoma became refractory to interferon α and sunitinib therapies. He started treatment with axitinib at 10 mg/day, and the dose was gradually tapered down to 4 mg/day because of intolerable adverse events. His metastatic lesions shrank; however, he could not continue due to the adverse events. He started fourth-line therapy with nivolumab; however, the metastatic lesions increased. Rechallenge with axitinib 4 mg/day was started, and the dose was reduced to 2 mg/day because of adverse events. Subsequently, the adverse events became controllable, and the metastatic lesions were maintained at reduced size. Conclusion Therapeutic drug monitoring of axitinib could play an important role in the development of safe and effective therapeutic treatment and individualization of these medications. |
| first_indexed | 2024-12-14T03:08:15Z |
| format | Article |
| id | doaj.art-dc16bc4374304853b20f5a2d3595667e |
| institution | Directory Open Access Journal |
| issn | 1752-1947 |
| language | English |
| last_indexed | 2024-12-14T03:08:15Z |
| publishDate | 2019-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Medical Case Reports |
| spelling | doaj.art-dc16bc4374304853b20f5a2d3595667e2022-12-21T23:19:20ZengBMCJournal of Medical Case Reports1752-19472019-04-011311510.1186/s13256-019-2041-8Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case reportMasaki Murata0Yohei Ikeda1Go Hasegawa2Yuki Nakagawa3Tsutomu Nishiyama4Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental HospitalDepartment of Diagnostic Radiology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental HospitalDepartment of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental HospitalDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental HospitalDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental HospitalAbstract Background There is no established treatment after failure of proven therapies for patients with metastatic renal cell carcinoma. Case presentation A 66-year-old Japanese man with metastatic renal cell carcinoma became refractory to interferon α and sunitinib therapies. He started treatment with axitinib at 10 mg/day, and the dose was gradually tapered down to 4 mg/day because of intolerable adverse events. His metastatic lesions shrank; however, he could not continue due to the adverse events. He started fourth-line therapy with nivolumab; however, the metastatic lesions increased. Rechallenge with axitinib 4 mg/day was started, and the dose was reduced to 2 mg/day because of adverse events. Subsequently, the adverse events became controllable, and the metastatic lesions were maintained at reduced size. Conclusion Therapeutic drug monitoring of axitinib could play an important role in the development of safe and effective therapeutic treatment and individualization of these medications.http://link.springer.com/article/10.1186/s13256-019-2041-8Metastatic renal cell carcinomaAdverse eventsLow-dose axitinib |
| spellingShingle | Masaki Murata Yohei Ikeda Go Hasegawa Yuki Nakagawa Tsutomu Nishiyama Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report Journal of Medical Case Reports Metastatic renal cell carcinoma Adverse events Low-dose axitinib |
| title | Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report |
| title_full | Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report |
| title_fullStr | Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report |
| title_full_unstemmed | Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report |
| title_short | Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report |
| title_sort | low dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α sunitinib axitinib and nivolumab therapies a case report |
| topic | Metastatic renal cell carcinoma Adverse events Low-dose axitinib |
| url | http://link.springer.com/article/10.1186/s13256-019-2041-8 |
| work_keys_str_mv | AT masakimurata lowdoseaxitinibrechallengewithpositiveoutcomesinapatientwithmetastaticrenalcellcarcinomarefractorytointerferonasunitinibaxitinibandnivolumabtherapiesacasereport AT yoheiikeda lowdoseaxitinibrechallengewithpositiveoutcomesinapatientwithmetastaticrenalcellcarcinomarefractorytointerferonasunitinibaxitinibandnivolumabtherapiesacasereport AT gohasegawa lowdoseaxitinibrechallengewithpositiveoutcomesinapatientwithmetastaticrenalcellcarcinomarefractorytointerferonasunitinibaxitinibandnivolumabtherapiesacasereport AT yukinakagawa lowdoseaxitinibrechallengewithpositiveoutcomesinapatientwithmetastaticrenalcellcarcinomarefractorytointerferonasunitinibaxitinibandnivolumabtherapiesacasereport AT tsutomunishiyama lowdoseaxitinibrechallengewithpositiveoutcomesinapatientwithmetastaticrenalcellcarcinomarefractorytointerferonasunitinibaxitinibandnivolumabtherapiesacasereport |